Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

NCT05000450 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated (Halted Prematurely)

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

GENETIC: ALLO-605
BIOLOGICAL: ALLO-647
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Allogene Therapeutics